Swedish Orphan Biovitrum has announced that it intends to discontinue discovery/early research and partner R&D programmes outside its core focus areas. The new focus of the R&D organisation is expected
Nordic Life Science
NLS Pharma News
Pharma
The European Commission has granted marketing authorisation for Esperoct for the treatment of adolescents and adults with haemophilia A. The authorisation covers all 28 European Union member states. About Esperoct
In January 2019 an evaluation of a number of new potential methods in an improved analysis model was initiated, which makes it possible to assess the tolerogenic effect on human
AstraZeneca and MSD have announced that the European Commission (EC) and the Japanese Ministry of Health, Labour and Welfare have approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with
The purpose is to strengthen knowledge transfer from academic research to clinical application and commercialization. The Board consists of five internationally reputable experts with extensive experience in research into diabetes
The company demonstrated a significant reduction in time on the waitlist for patients treated with imlifidase compared to matched controls at the 2019 American Transplant Congress, June 1 – 5, in
Clinical trials
The company has announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage
The company has announced that the first patient has been enrolled in the fimaChem RELEASE study with registration intent in
The company has submitted clinical trial authorization (CTA) application to initiate a Phase I study of its fully owned 4-1BB
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead
The company has announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology
The company has completed and announces positive results from the its Phase I/II clinical trial examining the safety and tolerability
Findings presented from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance (empagliflozin 25 mg) in PIONEER
Data from the company’s Phase 1/2 O-12-M1 clinical study of lead candidate melflufen demonstrate that melflufen may offer positive disease stabilization
The company has completed treatment of 25% of patients in the STAR trial of its medical device, SiPore15, and is
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The
The company announces initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the management of acute
The company has completed patient enrollment in the phase Ib/II trial of ONCOS-102 in combination with chemotherapy in unresectable malignant
The company has announced positive results from their Phase III ASCEND trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic
The company has completed a phase IIB randomized, double-blind, placebo-controlled trial in Finnish travellers going to Benin in West Africa.
The topline results from the 12-month follow-up review of the Phase 1 Lymfactin trial in breast cancer-associated lymphedema has been
The Permanent Secretary at Ministry of Health Dr Kennedy Malama together with the Swedish Ambassador Henrik Cederin, Dr Izukanji Sikazwe
Profiles in Pharma
She joined LEO Pharma by chance, more than 27 years ago, but she remained there, for the true focus on
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments